F10 and autoimmune polyendocrinopathy: In particular, Yang et al. reported that 5 of 38 APS patients (13.2%) had anti-FXa IgG and found that three of six monoclonal anti-FXa IgG significantly inhibited the inactivation of FXa by AT-III [11].